To further determine the importance of lipogenesis in the cell proliferative response of TKI-resistant ALK + lung cancer cells, we evaluated the effect of fatostatin, a small molecule inhibitor that hinders the trafficking of SREBP-1 to the Golgi compartment and thereby its proteolytic cleavage and activation. This evidence concerns the gene SREBF1 and lung cancer.